Skip to main content
Erschienen in: Annals of Hematology 2/2012

01.02.2012 | Review Article

Postpartum anemia II: prevention and treatment

verfasst von: Nils Milman

Erschienen in: Annals of Hematology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

This review focuses on the prevention and treatment of anemia in women who have just given childbirth (postpartum anemia). The problem of anemia both prepartum and postpartum is far more prevalent in developing countries than in the Western societies. The conditions for mother and child in the postpartum, nursing, and lactation period should be as favorable as possible. Many young mothers have a troublesome life due to iron deficiency and iron deficiency anemia (IDA) causing a plethora of symptoms including fatigue, physical disability, cognitive problems, and psychiatric disorders. Routine screening for postpartum anemia should be considered as part of the national maternal health programs. Major causes of postpartum anemia are prepartum iron deficiency and IDA in combination with excessive blood losses at delivery. Postpartum anemia should be defined as a hemoglobin level of <110 g/l at 1 week postpartum and <120 g/l at 8 weeks postpartum. Bleeding exceeding normal blood losses of approximately 300 ml may lead to rapid depletion of body iron reserves and may, unless treated, elicit long-standing iron deficiency and IDA in the postpartum period. The prophylaxis of postpartum anemia should begin already in early pregnancy in order to ensure a good iron status prior to delivery. The most reliable way to obtain this goal is to give prophylactic oral ferrous iron supplements 30–50 mg daily from early pregnancy and take obstetric precautions in pregnancies at risk for complications. In the treatment of slight-to-moderate postpartum IDA, the first choice should be oral ferrous iron 100 to 200 mg daily; it is essential to analyze hemoglobin after approximately 2 weeks in order to check whether treatment works. In severe IDA, intravenous ferric iron in doses ranging from 800 to 1,500 mg should be considered as first choice. In a few women with severe anemia and blunted erythropoiesis due to infection and/or inflammation, additional recombinant human erythropoietin may be considered. Blood transfusion should be restricted to women who develop circulatory instability due to postpartum hemorrhage. National health authorities should establish guidelines to combat iron deficiency in pregnancy and postpartum in order to facilitate a prosperous future for both mothers and children in a continuing globalized world.
Literatur
1.
Zurück zum Zitat Milman N (2011) Postpartum anemia I: definition, prevalence, causes and consequences. Ann Hematol 90:1247–1253PubMedCrossRef Milman N (2011) Postpartum anemia I: definition, prevalence, causes and consequences. Ann Hematol 90:1247–1253PubMedCrossRef
2.
Zurück zum Zitat Milman N. Anemia—still a major health problem in many parts of the world! Ann Hematol 2011; 90:369–377. http://dx.doi.org/10.1007/s00277-010-1144-5 Milman N. Anemia—still a major health problem in many parts of the world! Ann Hematol 2011; 90:369–377. http://​dx.​doi.​org/​10.​1007/​s00277-010-1144-5
3.
Zurück zum Zitat World Health Organization (1999) Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World Bank statement. World Health Organization, Geneva World Health Organization (1999) Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World Bank statement. World Health Organization, Geneva
4.
Zurück zum Zitat Potts M, Campbell M (2004) Three meetings and fewer funerals: misoprostol in postpartum hemorrhage. Lancet 364:1110–1111PubMedCrossRef Potts M, Campbell M (2004) Three meetings and fewer funerals: misoprostol in postpartum hemorrhage. Lancet 364:1110–1111PubMedCrossRef
5.
Zurück zum Zitat Tsu VD, Shane B (2004) New and underutilized technologies to reduce maternal mortality: call to action from a Bellagio workshop. Int J Gynecol Obstet 85(Suppl 1):S83–S93CrossRef Tsu VD, Shane B (2004) New and underutilized technologies to reduce maternal mortality: call to action from a Bellagio workshop. Int J Gynecol Obstet 85(Suppl 1):S83–S93CrossRef
6.
Zurück zum Zitat Bodnar LM, Siega-Riz AM, Miller WC, Cogswell ME, McDonald T (2002) Who should be screened for postpartum anemia? An evaluation of current recommendations. Am J Epidemiol 156:903–912PubMedCrossRef Bodnar LM, Siega-Riz AM, Miller WC, Cogswell ME, McDonald T (2002) Who should be screened for postpartum anemia? An evaluation of current recommendations. Am J Epidemiol 156:903–912PubMedCrossRef
7.
Zurück zum Zitat Bergmann RL, Richter R, Bergmann KE, Dudenhausen JW (2010) Prevalence and risk factors for early postpartum anemia. Eur J Obstet Gynecol Reprod Biol 150:126–131PubMedCrossRef Bergmann RL, Richter R, Bergmann KE, Dudenhausen JW (2010) Prevalence and risk factors for early postpartum anemia. Eur J Obstet Gynecol Reprod Biol 150:126–131PubMedCrossRef
8.
Zurück zum Zitat Milman N, Kirchhoff M (1992) Iron stores in 1359, 30- to 60-year-old Danish women: evaluation by serum ferritin and hemoglobin. Ann Hematol 64:22–227PubMedCrossRef Milman N, Kirchhoff M (1992) Iron stores in 1359, 30- to 60-year-old Danish women: evaluation by serum ferritin and hemoglobin. Ann Hematol 64:22–227PubMedCrossRef
9.
10.
Zurück zum Zitat Oyelese Y, Ananth CV (2010) Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol 53:147–156PubMedCrossRef Oyelese Y, Ananth CV (2010) Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol 53:147–156PubMedCrossRef
12.
Zurück zum Zitat Milman N, Agger OA, Nielsen OJ (1991) Iron supplementation during pregnancy. Effect on iron status markers, serum erythropoietin and human placental lactogen. A placebo controlled study in 207 Danish women. Dan Med Bull 38:471–476PubMed Milman N, Agger OA, Nielsen OJ (1991) Iron supplementation during pregnancy. Effect on iron status markers, serum erythropoietin and human placental lactogen. A placebo controlled study in 207 Danish women. Dan Med Bull 38:471–476PubMed
13.
Zurück zum Zitat Åkesson A, Bjellerup P, Berglund M, Bremme K, Vahter M (2002) Soluble transferrin receptor: longitudinal assessment from pregnancy to postlactation. Obstet Gynecol 99:260–266PubMedCrossRef Åkesson A, Bjellerup P, Berglund M, Bremme K, Vahter M (2002) Soluble transferrin receptor: longitudinal assessment from pregnancy to postlactation. Obstet Gynecol 99:260–266PubMedCrossRef
14.
Zurück zum Zitat World Health Organization. Iron deficiency anemia. Assessment, prevention and control. 2001;WHO/NHD/01.3 World Health Organization. Iron deficiency anemia. Assessment, prevention and control. 2001;WHO/NHD/01.3
15.
Zurück zum Zitat Milman N, Bergholt T, Eriksen L, Byg K-E, Graudal N, Pedersen P, Hertz J (2005) iron prophylaxis during pregnancy—how much iron is needed? A randomised, controlled study of 20 to 80 mg ferrous iron daily to pregnant women. Acta Obstet Gynecol Scand 84:238–247PubMed Milman N, Bergholt T, Eriksen L, Byg K-E, Graudal N, Pedersen P, Hertz J (2005) iron prophylaxis during pregnancy—how much iron is needed? A randomised, controlled study of 20 to 80 mg ferrous iron daily to pregnant women. Acta Obstet Gynecol Scand 84:238–247PubMed
16.
17.
Zurück zum Zitat Bothwell TH (2000) Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr 72:257S–264SPubMed Bothwell TH (2000) Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr 72:257S–264SPubMed
18.
Zurück zum Zitat Siimes MA, Vuori E, Kuitunen P (1979) Breast milk iron—a declining concentration during the course of lactation. Acta Paed Scand 68:29–31CrossRef Siimes MA, Vuori E, Kuitunen P (1979) Breast milk iron—a declining concentration during the course of lactation. Acta Paed Scand 68:29–31CrossRef
19.
Zurück zum Zitat Pedersen AN, Fagt S, Groth MV, Christensen T, Biltoft-Jensen, Matthiessen J, et al. Dietary habits in Denmark 2003–2008. Main results: National Food Agency of Denmark. 2010 Pedersen AN, Fagt S, Groth MV, Christensen T, Biltoft-Jensen, Matthiessen J, et al. Dietary habits in Denmark 2003–2008. Main results: National Food Agency of Denmark. 2010
20.
Zurück zum Zitat Commission of the European Communities. Nutrient and energy intakes for the European Community. Reports of the Scientific Committee for Food. Directorate General Industry 1993;31st series:180–181 Commission of the European Communities. Nutrient and energy intakes for the European Community. Reports of the Scientific Committee for Food. Directorate General Industry 1993;31st series:180–181
21.
Zurück zum Zitat National Collaborating Centre for Women's & Children's Health. NICE Clinical Guideline 62—Antenatal Care; March 2008 National Collaborating Centre for Women's & Children's Health. NICE Clinical Guideline 62—Antenatal Care; March 2008
23.
Zurück zum Zitat Recommendations CDC (1998) to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 47:1–29 Recommendations CDC (1998) to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 47:1–29
27.
Zurück zum Zitat Swedish Society for Obstetrics and Gynecology. Maternal health, sexual and reproductive health (Mödrahälsovård, sexuell och reproduktiv hälsa) 2008;rapport no. 59:47–48 Swedish Society for Obstetrics and Gynecology. Maternal health, sexual and reproductive health (Mödrahälsovård, sexuell och reproduktiv hälsa) 2008;rapport no. 59:47–48
28.
Zurück zum Zitat Trygg K, Lund-Larsen K, Sandstad B, Hoffman HJ, Jacobsen G, Bakketeig LS (1995) Do pregnant smokers eat differently from pregnant non-smokers? Paediatr Perinat Epidemiol 9:307–319PubMedCrossRef Trygg K, Lund-Larsen K, Sandstad B, Hoffman HJ, Jacobsen G, Bakketeig LS (1995) Do pregnant smokers eat differently from pregnant non-smokers? Paediatr Perinat Epidemiol 9:307–319PubMedCrossRef
29.
Zurück zum Zitat Nordic Council of Ministers. Nordic Nutrition Recommendations 2004. Copenhagen 2004 Nordic Council of Ministers. Nordic Nutrition Recommendations 2004. Copenhagen 2004
30.
Zurück zum Zitat Milman N, Byg K-E, Bergholt T, Eriksen L, Hvas A-M (2006) Body iron and individual iron prophylaxis in pregnancy—should the iron dose be adjusted according to serum ferritin? Ann Hematol 85:567–573PubMedCrossRef Milman N, Byg K-E, Bergholt T, Eriksen L, Hvas A-M (2006) Body iron and individual iron prophylaxis in pregnancy—should the iron dose be adjusted according to serum ferritin? Ann Hematol 85:567–573PubMedCrossRef
31.
Zurück zum Zitat Milman N (2006) Iron prophylaxis in pregnancy—general or individual and in which dose? Ann Hematol 85:821–828PubMedCrossRef Milman N (2006) Iron prophylaxis in pregnancy—general or individual and in which dose? Ann Hematol 85:821–828PubMedCrossRef
32.
Zurück zum Zitat Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnostik und Therapie der Anämie in der Schwangerschaft und postpartal. Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe. Expertenbrief 2007 no. 22 Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnostik und Therapie der Anämie in der Schwangerschaft und postpartal. Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe. Expertenbrief 2007 no. 22
33.
Zurück zum Zitat Beris P, Maniatis A, on behalf of the NATA working group on intravenous iron therapy. Guidelines on intravenous iron supplementation in surgery and obstetrics/gynecology. Transfusion Alternatives in Transfusion Medicine 2007;9 Suppl 1:29 Beris P, Maniatis A, on behalf of the NATA working group on intravenous iron therapy. Guidelines on intravenous iron supplementation in surgery and obstetrics/gynecology. Transfusion Alternatives in Transfusion Medicine 2007;9 Suppl 1:29
34.
Zurück zum Zitat ACOG Practice Bulletin (2006) clinical management guidelines for obstetrician/gynecologists number 76, 2006: postpartum hemorrhage. Obstet Gynecol 108:1039–1047CrossRef ACOG Practice Bulletin (2006) clinical management guidelines for obstetrician/gynecologists number 76, 2006: postpartum hemorrhage. Obstet Gynecol 108:1039–1047CrossRef
36.
Zurück zum Zitat Rajan PV, Wing DA (2010) Postpartum hemorrhage: evidence-based medical interventions for prevention and treatment. Clin Obstet Gynecol 53:165–181PubMedCrossRef Rajan PV, Wing DA (2010) Postpartum hemorrhage: evidence-based medical interventions for prevention and treatment. Clin Obstet Gynecol 53:165–181PubMedCrossRef
37.
Zurück zum Zitat Russell RT. WHO guidelines for the management of postpartum haemorrhage and retained placenta. World Health Organization WHO Press, Geneva, Switzerland, 2009, ISBN 978-92-4-159851-4 Russell RT. WHO guidelines for the management of postpartum haemorrhage and retained placenta. World Health Organization WHO Press, Geneva, Switzerland, 2009, ISBN 978-92-4-159851-4
38.
Zurück zum Zitat Dar S, Vardi IS, Holcberg G, Reuveni H, Yerushalmi R, Katz M, Sheiner E (2006) Do we need routine complete blood count following vaginal delivery? Int J Fertil Womens Med 51:270–273PubMed Dar S, Vardi IS, Holcberg G, Reuveni H, Yerushalmi R, Katz M, Sheiner E (2006) Do we need routine complete blood count following vaginal delivery? Int J Fertil Womens Med 51:270–273PubMed
39.
Zurück zum Zitat Recommendation to prevent and control iron deficiency in the United States. MMWR Morb Mortal Wkly Rep 1998; 47(RR-3):13–25 Recommendation to prevent and control iron deficiency in the United States. MMWR Morb Mortal Wkly Rep 1998; 47(RR-3):13–25
40.
41.
Zurück zum Zitat Skikne B, Baynes RD (1994) Iron absorption. In: Brock JH, Halliday JW, Pippard MJ, Powell LW (eds) iron metabolism in health and disease. Saunders, London, pp 151–187 Skikne B, Baynes RD (1994) Iron absorption. In: Brock JH, Halliday JW, Pippard MJ, Powell LW (eds) iron metabolism in health and disease. Saunders, London, pp 151–187
42.
Zurück zum Zitat Milman N, Graudal N, Nielsen OJ, Agger AO (1997) Serum erythropoietin during normal pregnancy: relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol 66:159–168PubMedCrossRef Milman N, Graudal N, Nielsen OJ, Agger AO (1997) Serum erythropoietin during normal pregnancy: relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol 66:159–168PubMedCrossRef
43.
Zurück zum Zitat Krafft A, Breymann C (2011) Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. J Obstet Gynaecol Res 37:119–124PubMedCrossRef Krafft A, Breymann C (2011) Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. J Obstet Gynaecol Res 37:119–124PubMedCrossRef
44.
Zurück zum Zitat Nielsen JB, Ikkala E, Sölvell L, Björn-Rasmussen E, Ekenved G (1976) Absorption of iron from slow-release and rapidly-disintegrating tablets—a comparative study in normal subjects, blood donors and subjects with iron deficiency anemia. Scand J Haematol Suppl 28:89–97PubMed Nielsen JB, Ikkala E, Sölvell L, Björn-Rasmussen E, Ekenved G (1976) Absorption of iron from slow-release and rapidly-disintegrating tablets—a comparative study in normal subjects, blood donors and subjects with iron deficiency anemia. Scand J Haematol Suppl 28:89–97PubMed
48.
Zurück zum Zitat Lyseng-Williamson KA, Keating GM (2009) Ferric carboxymaltose: a review of its use in iron-deficiency anemia. Drugs 69:739–756PubMedCrossRef Lyseng-Williamson KA, Keating GM (2009) Ferric carboxymaltose: a review of its use in iron-deficiency anemia. Drugs 69:739–756PubMedCrossRef
50.
Zurück zum Zitat al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T et al (1996) Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 69:121–124PubMedCrossRef al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T et al (1996) Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 69:121–124PubMedCrossRef
51.
Zurück zum Zitat al-Ragip A, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A (2005) Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 106:1335–1340CrossRef al-Ragip A, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A (2005) Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 106:1335–1340CrossRef
52.
Zurück zum Zitat Hallak M, Sharon A, Duikman R, Auslender R, Abramovici H (1997) Supplementation iron intravenously in pregnancy. A way to avoid blood transfusions. J Reprod Med 42:99–103PubMed Hallak M, Sharon A, Duikman R, Auslender R, Abramovici H (1997) Supplementation iron intravenously in pregnancy. A way to avoid blood transfusions. J Reprod Med 42:99–103PubMed
53.
Zurück zum Zitat Breymann C, Visca E, Huch R, Huch A (2001) Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. Am J Obstet Gynecol 184:662–667PubMedCrossRef Breymann C, Visca E, Huch R, Huch A (2001) Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. Am J Obstet Gynecol 184:662–667PubMedCrossRef
54.
Zurück zum Zitat Bashiri A, Burstein E, Sheiner E, Mazor M (2003) Anemia during pregnancy and treatment with intravenous iron: review of the literature. Eur J Obstet Gynecol Reprod Biol 110:2–7PubMedCrossRef Bashiri A, Burstein E, Sheiner E, Mazor M (2003) Anemia during pregnancy and treatment with intravenous iron: review of the literature. Eur J Obstet Gynecol Reprod Biol 110:2–7PubMedCrossRef
55.
Zurück zum Zitat Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A (2007) Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia. A randomised controlled trial. Obstet Gynecol 110:267–278PubMedCrossRef Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A (2007) Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia. A randomised controlled trial. Obstet Gynecol 110:267–278PubMedCrossRef
56.
Zurück zum Zitat Breymann C, Richter C, Hüttner C, Huch R, Huch A (2000) Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anemia and blunted erythropoiesis. Eur J Clin Invest 30:154–161PubMedCrossRef Breymann C, Richter C, Hüttner C, Huch R, Huch A (2000) Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anemia and blunted erythropoiesis. Eur J Clin Invest 30:154–161PubMedCrossRef
57.
Zurück zum Zitat Bhandal N, Russell R (2006) Intravenous versus oral iron therapy for postpartum anemia. BJOG 113:1248–1252PubMedCrossRef Bhandal N, Russell R (2006) Intravenous versus oral iron therapy for postpartum anemia. BJOG 113:1248–1252PubMedCrossRef
58.
Zurück zum Zitat Giannoulis C, Daniilidis A, Tantanasis T, Dinas K, Tzafettas J (2009) Intravenous administration of iron sucrose for treating anemia in postpartum women. Hippokratia 13:38–40PubMed Giannoulis C, Daniilidis A, Tantanasis T, Dinas K, Tzafettas J (2009) Intravenous administration of iron sucrose for treating anemia in postpartum women. Hippokratia 13:38–40PubMed
59.
Zurück zum Zitat Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R (2008) Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obst Gynecol 199:435e1–435e7CrossRef Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R (2008) Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obst Gynecol 199:435e1–435e7CrossRef
60.
Zurück zum Zitat Westad S, Backe B, Salvesen KÅ, Nakling J, Økland I, Borthen I et al (2008) A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand 87:916–923PubMedCrossRef Westad S, Backe B, Salvesen KÅ, Nakling J, Økland I, Borthen I et al (2008) A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand 87:916–923PubMedCrossRef
61.
Zurück zum Zitat Ganzoni AM (1972) Totalinfusion von Ferri-Kohlenhydrat-Komplexen (Total infusion of ferri-carbohydrate complexes). Blut 25:349–351PubMedCrossRef Ganzoni AM (1972) Totalinfusion von Ferri-Kohlenhydrat-Komplexen (Total infusion of ferri-carbohydrate complexes). Blut 25:349–351PubMedCrossRef
63.
Zurück zum Zitat Kotto-Kome AC, Calhoun DA, Montenegro R, Sosa R, Maldonado L, Christensen RD (2004) Effect of administering recombinant erythropoietin to women with postpartum anemia: a meta-analysis. J Perinatol 24:11–15PubMedCrossRef Kotto-Kome AC, Calhoun DA, Montenegro R, Sosa R, Maldonado L, Christensen RD (2004) Effect of administering recombinant erythropoietin to women with postpartum anemia: a meta-analysis. J Perinatol 24:11–15PubMedCrossRef
64.
Zurück zum Zitat Wågström E, Åkesson A, Van Rooijen M, Larson B, Bremme K (2007) Erythropoietin and intravenous iron therapy in postpartum anemia. Acta Obstet Gynecol Scand 86:957–962PubMedCrossRef Wågström E, Åkesson A, Van Rooijen M, Larson B, Bremme K (2007) Erythropoietin and intravenous iron therapy in postpartum anemia. Acta Obstet Gynecol Scand 86:957–962PubMedCrossRef
65.
Zurück zum Zitat Lebrecth A, Häberlin f, Eberhard J (1995) Anämie im Wochenbett; parenterale Eisensubstitution macht Erythropoietin-Therapie entberlich (Postpartum anaemia; intravenous iron supplementation renders therapy with rhEPO redundant). Geburtshilfe Frauenheilkd 55:167–170CrossRef Lebrecth A, Häberlin f, Eberhard J (1995) Anämie im Wochenbett; parenterale Eisensubstitution macht Erythropoietin-Therapie entberlich (Postpartum anaemia; intravenous iron supplementation renders therapy with rhEPO redundant). Geburtshilfe Frauenheilkd 55:167–170CrossRef
66.
Zurück zum Zitat Breymann c, Zimmermann R, Huch A (1996) Use of recombinant erythropoietin in combination with parenteral iron in the treatment of postpartum anemia. Eur J Clin Invest 26:123–130PubMedCrossRef Breymann c, Zimmermann R, Huch A (1996) Use of recombinant erythropoietin in combination with parenteral iron in the treatment of postpartum anemia. Eur J Clin Invest 26:123–130PubMedCrossRef
67.
Zurück zum Zitat Macrydimas G, Lolis G, Lialios G, Tsiara S, Georgiou I, Bourantas KL (1998) Recombinant human erythropoietin treatment of postpartum anemia. Preliminary results. Eur J Obstet Gynecol Reprod Biol 81:27–31CrossRef Macrydimas G, Lolis G, Lialios G, Tsiara S, Georgiou I, Bourantas KL (1998) Recombinant human erythropoietin treatment of postpartum anemia. Preliminary results. Eur J Obstet Gynecol Reprod Biol 81:27–31CrossRef
68.
Zurück zum Zitat Gyamfi C, Berkowitz RL (2007) Management of pregnancy in a Jehova's Witness. Obs Gynecol Clin N Am 34:357–365CrossRef Gyamfi C, Berkowitz RL (2007) Management of pregnancy in a Jehova's Witness. Obs Gynecol Clin N Am 34:357–365CrossRef
70.
Zurück zum Zitat Roberts CL, Ford JB, Thomson JF, Morris JM (2008) Population rates of hemorrhage and transfusions among obstetric patients in NSW: a short communication. Aust N Z J Obstet Gynaecol 48:481–484PubMedCrossRef Roberts CL, Ford JB, Thomson JF, Morris JM (2008) Population rates of hemorrhage and transfusions among obstetric patients in NSW: a short communication. Aust N Z J Obstet Gynaecol 48:481–484PubMedCrossRef
71.
Zurück zum Zitat Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B (2008) Prevalence and risk factors of severe obstetric hemorrhage. BJOG 115:1265–1272PubMedCrossRef Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B (2008) Prevalence and risk factors of severe obstetric hemorrhage. BJOG 115:1265–1272PubMedCrossRef
72.
Zurück zum Zitat Rouse DJ, MacPherson C, Landon M, Varner MW, Leveno KJ, Moawad AH et al (2006) Blood transfusion and cesarean delivery. Obstet Gynecol 108:891–897PubMedCrossRef Rouse DJ, MacPherson C, Landon M, Varner MW, Leveno KJ, Moawad AH et al (2006) Blood transfusion and cesarean delivery. Obstet Gynecol 108:891–897PubMedCrossRef
73.
Zurück zum Zitat Fuller AJ, Bucklin BA (2010) Blood product replacement for postpartum hemorrhage. Clin Obstet Gynecol 53:196–208PubMedCrossRef Fuller AJ, Bucklin BA (2010) Blood product replacement for postpartum hemorrhage. Clin Obstet Gynecol 53:196–208PubMedCrossRef
Metadaten
Titel
Postpartum anemia II: prevention and treatment
verfasst von
Nils Milman
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 2/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1381-2

Weitere Artikel der Ausgabe 2/2012

Annals of Hematology 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.